Skip to content
Open access

Genome-wide CRISPR Identification of Regulators Governing the NLRP3 Inflammasome 2331537

Jul 2026 · Journal of Immunology · Vol 215 · 0 citations

TL;DR

A comprehensive genetic landscape governing human NLRP3 inflammasome activation is defined and novel regulatory nodes that decouple inflammasome assembly from upstream priming are uncovered.

Abstract

Dysregulated NLRP3 inflammasome activation drives chronic inflammation in autoimmune and autoinflammatory diseases. Sustained NLRP3-dependent IL-1β production promotes tissue damage, yet current therapies rely on broad immunosuppression or cytokine blockade that can impair host defense and provide incomplete disease control. Although direct NLRP3 inhibitors are emerging, their utility is limited by toxicity and an incomplete understanding of inflammasome regulation. Defining genetic networks that tune inflammasome activation is therefore critical for identifying therapeutic targets that selectively limit pathological inflammation while preserving protective innate immune responses. We conducted a genome-wide CRISPR—Cas9 KO screen in human THP-1 macrophages stably expressing ASC-GFP to identify genetic regulators of NLRP3 inflammasome activation. After inflammasome activation, cells are sorted by flow cytometry based on ASC speck formation. Candidate genes were prioritized using enrichment statistics and pathway analysis. Top hits were validated using independent sgRNAs, with readouts including IL-1β ELISA and imaging-based ASC speck quantification. NF-κB phosphorylation was assessed to exclude false-positive regulators affecting inflammasome priming rather than activation. The screen robustly identified known NLRP3 pathway components, validating screen performance, and revealed multiple previously uncharacterized regulators spanning cytoskeletal dynamics, mitochondrial homeostasis, and ubiquitin signaling. Genetic perturbation of top candidates significantly altered IL-1β release without affecting NF-κB priming. Our study defines a comprehensive genetic landscape governing human NLRP3 inflammasome activation and uncovers novel regulatory nodes that decouple inflammasome assembly from upstream priming. These findings provide mechanistic insight into innate immune regulation and nominate new targets for selective therapeutic modulation of inflammasome-driven disease. n/a Innate Immune Responses and Host Defense: Molecular Mechanisms (INM)

Read PDF

Similar papers

Jul 2026

MEX3B as a Potent Regulator of Inflammasome Signaling 2267250

Deletion of MEX3B inhibited caspase-4 and gasdermin D activation, pyroptosis, and secretion of inflammasome-dependent inflammatory cytokines in human cell lines and murine primary macrophages and suggested that MEX3B is a pan-inflammasome regulator targeting inflammatory caspases.

Peng-Hua Wang, Jason G. Cahoon, Duo-Meng Yang et al. · 0 citations
Open access Jul 2026

NLRP3 confers regulatory T cell-mediated control of intestinal inflammation 2256029

A previously underappreciated anti-inflammatory role of NLRP3 in Tregs in controlling Th17 responses in the intestines is demonstrated and should guide effective therapies for intestinal disorders where the anti-inflammatory vs. proinflammatory role of NLRP3 is still debated.

Rasika Patkar, Justin Yip, Chia-Hao Lin et al. · 0 citations
Review Open access Sep 2026

The NLRP3 inflammasome at the crossroads of innate immune signaling and cell death.

The NLRP3 inflammasome is a central signaling pathway of innate immunity that orchestrates host defense and inflammatory responses through the activation of proinflammatory cytokines and the induction of pyroptotic cell death. Accumulating evidence indicates that NLRP3 functions within an extensive network of innate im...

Nan-Yang Xiao, Ze-Xuan Lu, Destiny K. Cooper et al. · 0 citations
Aug 2026

Vilazodone inhibits NLRP3 inflammasome assembly by targeting the NACHT domain and alleviates inflammatory disease.

The NLRP3 inflammasome plays a central role in innate immunity and inflammatory diseases, yet effective inhibitors remain limited. Here, we identified vilazodone, an FDA-approved antidepressant, as a potent inhibitor of NLRP3 inflammasome activation by small-molecule screening. Vilazodone significantly suppressed IL-1β...

Xiang-Yu Yang, Gui-Fang Xiong, Jie Yang et al. · 0 citations
Open access Jul 2026

TRIM21 Orchestrates Inflammasome Assembly and Drives Autoinflammatory Pathology 2300561

Inflammasomes are pivotal cytoplasmic scaffolds that drive the maturation of interleukin (IL)-1β and IL-18 and initiate pyroptotic cell death. Tight regulation of inflammasome activity is critical, as uncontrolled IL-1β release underlies chronic inflammation and autoinflammatory disease. The adaptor protein ASC i...

Jessica Carriere, Chawon Yun, Sonal Khare et al. · 0 citations
Jul 2026

Context-dependent cancer vulnerabilities: CRISPR screening under inflammatory stress.

Genome-wide CRISPR screens have systematically identified genes required for cancer cell survival, yet these studies are typically performed under standardized conditions that do not fully recapitulate the physiological stresses encountered within the tumor microenvironment. In a recent issue of Nature Genetics, Cherui...

Zihan Ning, Guangchuan Wang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.